Does heparin improve pregnancy outcomes for women with evidence of placental dysfunction? A randomised controlled trial

niversity of Toronto (Canada)0 个研究点目标入组 102 人开始时间: 2007年5月2日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Women with a singleton pregnancy at 18 to 22 weeks gestation
•2. Evidence of placental dysfunction in their current pregnancy as determined by two or more of the following:
•a. abnormal ultrasonographic placental morphology
•b. abnormal uterine artery Doppler waveforms
•c. one or more abnormal biochemical markers on first or second trimester maternal serum screening

•1. Women with known positive thrombophilic screening
•2. Known lethal foetal anomaly
•3. Any contraindication to heparin therapy or continuation of the pregnancy (e.g., chorioamnionitis requiring delivery)
•4. Clinical need for heparin therapy during pregnancy (e.g., previous venous thrombo-embolic episode)
•5. Multiple pregnancy
•6. Hypertension
•7. Language barrier requiring official translator

发起方

niversity of Toronto (Canada)